Drug Name: Vonjo
Indications: To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets.
Active Ingredient:
Company: CTI BioPharma Corp.
Approval Date: 2/28/2022
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf